About Protein tweety homolog 3
Protein tweety homolog 3 (TTYH3) is a protein
from Homo sapiens identified by UniProt accession
Q9C0H2, 523 residues long.
MolForge cross-references it against 0 known binders and
90 disease associations.
Target properties
| Protein name | Protein tweety homolog 3 |
| UniProt accession | Q9C0H2 |
| Gene | TTYH3 |
| Organism | Homo sapiens |
| Length | 523 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (90)
Diseases linked to this target (Open Targets).
- creatinine measurement · score 0.26
- platelet component distribution width · score 0.24
- glioblastoma multiforme · score 0.18
- appendicular lean mass · score 0.14
- head and neck squamous cell carcinoma · score 0.12
- hepatocellular carcinoma · score 0.08
- urinary bladder carcinoma · score 0.07
- breast cancer · score 0.07
- cancer · score 0.07
- body height · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9C0H2-F1 | alphafold | PREDICTED | 79.44 | — |
Amino-acid sequence (523 residues)
MAGVSYAAPW WVSLLHRLPH FDLSWEATSS QFRPEDTDYQ QALLLLGAAA LACLALDLLF LLFYSFWLCC RRRKSEEHLD ADCCCTAWCV IIATLVCSAG IAVGFYGNGE TSDGIHRATY SLRHANRTVA GVQDRVWDTA VGLNHTAEPS LQTLERQLAG RPEPLRAVQR LQGLLETLLG YTAAIPFWRN TAVSLEVLAE QVDLYDWYRW LGYLGLLLLD VIICLLVLVG LIRSSKGILV GVCLLGVLAL VISWGALGLE LAVSVGSSDF CVDPDAYVTK MVEEYSVLSG DILQYYLACS PRAANPFQQK LSGSHKALVE MQDVVAELLR TVPWEQPATK DPLLRVQEVL NGTEVNLQHL TALVDCRSLH LDYVQALTGF CYDGVEGLIY LALFSFVTAL MFSSIVCSVP HTWQQKRGPD EDGEEEAAPG PRQAHDSLYR VHMPSLYSCG SSYGSETSIP AAAHTVSNAP VTEYMSQNAN FQNPRCENTP LIGRESPPPS YTSSMRAKYL ATSQPRPDSS GSH
Explore Protein tweety homolog 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets